Home / Current Issue / Paper 1705974
The Silent Epidemic: Addressing Hepatitis C in the USA
Subject area: Science,Engineering and Technology · Area of research: Public Health
Abstract
Hepatitis C, a blood-borne viral infection, is a significant public health concern in the USA (Zein, 2019). It's a silent epidemic, often asymptomatic in its early stages, but can lead to liver cirrhosis, liver cancer, and even death if left untreated (Lauer & Walker, 2020). Despite its prevalence, Hepatitis C remains a neglected disease, with many individuals unaware of their infection status or lacking access to effective treatment (Denniston et al., 2014).
References
[1] Zein, N. (2019). Hepatitis C: A review of the epidemiology, diagnosis, and treatment. Journal of Clinical Gastroenterology, 53(8), 538-545.
[2] Lauer, G. M., & Walker, B. D. (2020). Hepatitis C virus infection. New England Journal of Medicine, 382(14), 1335-1346.
[3] Denniston, M. M., et al. (2014). Chronic hepatitis C virus infection in the United States: National Health and Nutrition Examination Survey 2003-2010. Annals of Internal Medicine, 160(5), 293-300.
[4] CDC. (2020). Hepatitis C questions and answers for the public. Centers for Disease Control and Prevention.
[5] Hagan, H., et al. (2019). Hepatitis C virus transmission and prevention. Journal of Infectious Diseases, 219(1), 1-8.
[6] AASLD. (2019). HCV guidance: Recommendations for testing, managing, and treating hepatitis C. American Association for the Study of Liver Diseases.
[7] Krawczynski, K., et al. (2019). Hepatitis C virus infection: Diagnosis and management. Journal of Clinical Virology, 112, 53-61.
[8] Squier, S., et al. (2019). Hepatitis C virus RNA detection: A review of the available assays. Journal of Medical Virology, 91(9), 1721-1729.
[9] Liu, S., et al. (2020). Direct-acting antivirals for hepatitis C virus infection: A systematic review and meta-analysis. Journal of Hepatology, 72(1), 13-24.
[10] Pawlotsky, J. M., et al. (2019). Hepatitis C virus treatment: A review of the current options. Journal of Hepatology, 70(1), 13-25.
[11] FDA. (2020). Hepatitis C treatment options. Food and Drug Administration.
How to cite this paper
@article{1705974,
author = {Omotosho Ajibola Adunola},
title = {The Silent Epidemic: Addressing Hepatitis C in the USA},
journal = {Iconic Research And Engineering Journals},
year = {2024},
volume = {7},
number = {12},
pages = {422-423},
issn = {2456-8880},
url = {https://www.irejournals.com/formatedpaper/1705974.pdf},
abstract = {Hepatitis C, a blood-borne viral infection, is a significant public health concern in the USA (Zein, 2019). It's a silent epidemic, often asymptomatic in its early stages, but can lead to liver cirrhosis, liver cancer, and even death if left untreated (Lauer & Walker, 2020). Despite its prevalence, Hepatitis C remains a neglected disease, with many individuals unaware of their infection status or lacking access to effective treatment (Denniston et al., 2014).},
month = {June},
}